Brokerages Set Monopar Therapeutics Inc. (NASDAQ:MNPR) PT at $118.67

Shares of Monopar Therapeutics Inc. (NASDAQ:MNPR) have been given a consensus rating of “Moderate Buy” by the fourteen ratings firms that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation, nine have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $118.6667.

Several research firms have recently weighed in on MNPR. HC Wainwright upped their target price on shares of Monopar Therapeutics from $105.00 to $125.00 and gave the stock a “buy” rating in a report on Wednesday, July 22nd. Piper Sandler set a $105.00 target price on shares of Monopar Therapeutics in a research note on Tuesday, June 2nd. BTIG Research raised their price target on Monopar Therapeutics from $117.00 to $133.00 and gave the company a “buy” rating in a report on Wednesday, August 12th. Morgan Stanley restated an “overweight” rating and set a $130.00 target price on shares of Monopar Therapeutics in a report on Monday, August 17th. Finally, Cantor Fitzgerald cut Monopar Therapeutics from an “overweight” rating to a “neutral” rating and lifted their price target for the company from $109.00 to $119.00 in a report on Thursday, August 13th.

Institutional Trading of Monopar Therapeutics

Several hedge funds have recently modified their holdings of the stock. Russell Investments Group Ltd. acquired a new stake in shares of Monopar Therapeutics in the 3rd quarter valued at $28,000. BNP Paribas Financial Markets lifted its stake in shares of Monopar Therapeutics by 100.6% during the third quarter. BNP Paribas Financial Markets now owns 696 shares of the company’s stock valued at $57,000 after acquiring an additional 349 shares during the period. Sei Investments Co. boosted its holdings in Monopar Therapeutics by 9.5% in the first quarter. Sei Investments Co. now owns 7,582 shares of the company’s stock valued at $415,000 after acquiring an additional 656 shares during the last quarter. Meeder Asset Management Inc. bought a new position in Monopar Therapeutics in the fourth quarter valued at about $65,000. Finally, Caitong International Asset Management Co. Ltd acquired a new stake in Monopar Therapeutics in the fourth quarter worth about $86,000. 1.83% of the stock is owned by institutional investors.

Monopar Therapeutics Trading Up 2.6%

MNPR stock opened at $113.72 on Friday. Monopar Therapeutics has a 1-year low of $32.04 and a 1-year high of $124.82. The firm has a market cap of $763.06 million, a P/E ratio of -52.41 and a beta of 1.47. The business’s 50 day moving average is $104.63 and its 200-day moving average is $74.34.

Monopar Therapeutics (NASDAQ:MNPR) last posted its earnings results on Wednesday, August 12th. The company reported ($0.62) EPS for the quarter, topping the consensus estimate of ($0.64) by $0.02. Sell-side analysts forecast that Monopar Therapeutics will post -2.94 EPS for the current year.

Monopar Therapeutics Company Profile

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.